About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue. At least two of those questions, had they been asked just a month or so later, would have surely yielded very different responses than they did in December 2019: What impact would a U.S. economic slowdown have on biopharma manufacturing, and what should biopharma do in the next three to five years to reduce risk to global supply chains posed by natural disasters?